Eli Lilly and [LLY] vs Amgen [AMGN] Detailed Stock Comparison
Eli Lilly and
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eli Lilly and wins in 10 metrics, Amgen wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Eli Lilly and | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.24 | 27.44 | Amgen |
| Price-to-Book Ratio | 48.58 | 26.10 | Amgen |
| Debt-to-Equity Ratio | 243.61 | 924.46 | Eli Lilly and |
| PEG Ratio | 35.66 | 14.58 | Amgen |
| EV/EBITDA | 34.58 | 13.39 | Amgen |
| Profit Margin (TTM) | 22.67% | 17.39% | Eli Lilly and |
| Operating Margin (TTM) | 42.49% | 28.73% | Eli Lilly and |
| EBITDA Margin (TTM) | 42.49% | 28.73% | Eli Lilly and |
| Return on Equity | 77.28% | 105.67% | Amgen |
| Return on Assets (TTM) | 16.45% | 7.04% | Eli Lilly and |
| Free Cash Flow (TTM) | $414.30M | $10.39B | Amgen |
| Dividend Yield | 0.52% | 3.20% | Amgen |
| 1-Year Return | -5.52% | -9.77% | Eli Lilly and |
| Price-to-Sales Ratio (TTM) | 14.89 | 4.75 | Amgen |
| Enterprise Value | $760.93B | $210.58B | Eli Lilly and |
| EV/Revenue Ratio | 15.53 | 6.17 | Amgen |
| Gross Profit Margin (TTM) | 82.53% | 63.58% | Eli Lilly and |
| Revenue per Share (TTM) | $54 | $63 | Amgen |
| Earnings per Share (Diluted) | $12.20 | $10.98 | Eli Lilly and |
| Beta (Stock Volatility) | 0.40 | 0.48 | Eli Lilly and |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Eli Lilly and vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eli Lilly and | -0.38% | -4.86% | -2.50% | -15.45% | -7.67% | -2.31% |
| Amgen | -0.72% | -2.54% | 7.94% | 3.59% | 6.11% | 16.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eli Lilly and | -5.52% | 152.25% | 397.01% | 823.88% | 1,961.51% | 1,322.04% |
| Amgen | -9.77% | 22.38% | 25.21% | 74.90% | 438.74% | 268.02% |
Performance & Financial Health Analysis: Eli Lilly and vs Amgen
| Metric | LLY | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $729.58B | $162.01B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 3,148,260 | 1,842,602 |
| 90 Day Avg. Volume | 3,058,507 | 2,429,634 |
| Last Close | $760.08 | $301.37 |
| 52 Week Range | $677.09 - $972.53 | $253.30 - $340.89 |
| % from 52W High | -21.85% | -11.59% |
| All-Time High | $972.53 (Aug 19, 2024) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -21.85% | -13.11% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.45% | 0.09% |
| Quarterly Earnings Growth | 0.23% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.23% | 0.17% |
| Operating Margin (TTM) | 0.42% | 0.29% |
| Return on Equity (TTM) | 0.77% | 1.06% |
| Debt to Equity (MRQ) | 243.61 | 924.46 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $16.64 | $11.54 |
| Cash per Share (MRQ) | $3.59 | $16.38 |
| Operating Cash Flow (TTM) | $9.32B | $12.19B |
| Levered Free Cash Flow (TTM) | $-1,821,975,040 | $13.09B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.52% | 3.20% |
| Last 12-Month Dividend | $4.10 | $9.26 |
Valuation & Enterprise Metrics Analysis: Eli Lilly and vs Amgen
| Metric | LLY | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.24 | 27.44 |
| Forward P/E | 35.66 | 14.58 |
| PEG Ratio | 35.66 | 14.58 |
| Price to Sales (TTM) | 14.89 | 4.75 |
| Price to Book (MRQ) | 48.58 | 26.10 |
| Market Capitalization | ||
| Market Capitalization | $729.58B | $162.01B |
| Enterprise Value | $760.93B | $210.58B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 15.53 | 6.17 |
| Enterprise to EBITDA | 34.58 | 13.39 |
| Risk & Other Metrics | ||
| Beta | 0.40 | 0.48 |
| Book Value per Share (MRQ) | $16.64 | $11.54 |
Financial Statements Comparison: Eli Lilly and vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LLY | AMGN |
|---|---|---|
| Revenue/Sales | $12.73B | $8.15B |
| Cost of Goods Sold | $2.22B | $2.97B |
| Gross Profit | $10.50B | $5.18B |
| Research & Development | $2.73B | $1.49B |
| Operating Income (EBIT) | $5.41B | $1.18B |
| EBITDA | $5.92B | $4.08B |
| Pre-Tax Income | $3.46B | $1.97B |
| Income Tax | $696.80M | $243.00M |
| Net Income (Profit) | $2.76B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LLY | AMGN |
|---|---|---|
| Cash & Equivalents | $3.09B | $8.81B |
| Total Current Assets | $41.26B | $26.93B |
| Total Current Liabilities | $30.07B | $23.01B |
| Long-Term Debt | $34.50B | $54.01B |
| Total Shareholders Equity | $15.85B | $6.21B |
| Retained Earnings | $15.10B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LLY | AMGN |
|---|---|---|
| Operating Cash Flow | $4.88B | $1.71B |
| Capital Expenditures | $-1.51B | $-411.00M |
| Free Cash Flow | $-1.60B | $980.00M |
| Debt Repayment | N/A | $-2.50B |
| Common Stock Repurchase | $-1.20B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | LLY | AMGN |
|---|---|---|
| Shares Short | 7.64M | 14.70M |
| Short Ratio | 2.48 | 5.46 |
| Short % of Float | 0.01% | 0.03% |
| Average Daily Volume (10 Day) | 3,148,260 | 1,842,602 |
| Average Daily Volume (90 Day) | 3,058,507 | 2,429,634 |
| Shares Outstanding | 897.54M | 537.00M |
| Float Shares | 895.49M | 536.32M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.84% | 0.84% |
Dividend Analysis & Yield Comparison: Eli Lilly and vs Amgen
| Metric | LLY | AMGN |
|---|---|---|
| Last 12-Month Dividend | $4.10 | $9.26 |
| Last 12-Month Dividend Yield | 0.52% | 3.20% |
| 3-Year Avg Annual Dividend | $4.02 | $8.72 |
| 3-Year Avg Dividend Yield | 0.22% | 0.79% |
| 3-Year Total Dividends | $12.05 | $26.16 |
| Ex-Dividend Date | Feb 14, 2025 | May 16, 2025 |